Organization (Academic)
University of Göttingen
ClinicalTrials.gov lists University of Göttingen as lead sponsor of 37 trials. It has 3 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 2 registered with a 2026 start date. The dashed outline is the pace from the 2 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 2.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Logo Georg-August-Universität Göttingen, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers University of Göttingen: 37 lead-sponsored trials and 1 legal-entity registration.
Disease areas (69)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Heart Failure | 6 |
| Schizophrenia | 6 |
| Coronary Disease | 4 |
| Substance-Related Disorders | 4 |
| Lymphoma | 3 |
Showing 5 of 69 disease areas.
Trials by start year as sponsor or collaborator (23)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 1 |
| 2024 | 4 |
| 2023 | 2 |
| 2022 | 3 |
| 2021 | 5 |
| 2020 | 3 |
| 2019 | 3 |
| 2018 | 5 |
| 2017 | 7 |
Showing 10 of 23 years.
Recruitment duration, a model prediction: none of the 37 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Approved assets (3)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| paroxetine + aerobic exercise | 1 |
| Paroxetine + relaxation | 1 |
| Alemtuzumab | 2 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 58% hit target (n=12) | 55% on time (n=11) |
Journals published in (112)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Stroke | 11 |
| Annals of the rheumatic diseases | 6 |
| Caries research | 5 |
| Clinical oral investigations | 5 |
| International journal of stroke : official journal of the International Stroke Society | 5 |
Showing 5 of 112 journals.
Organization relationships (21)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Sheba Medical Center | Co sponsors trial with | 1 |
| Nordic Lymphoma Group | Co sponsors trial with | 1 |
| Helmholtz Association of German Research Centres | Co sponsors trial with | 1 |
| Utah System of Higher Education | Co sponsors trial with | 1 |
| Assistance Publique – Hôpitaux de Paris | Co sponsors trial with | 1 |
Showing 5 of 21 relationships.
Latest dated events (71)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-01-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-01-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-05-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2024-06-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2024-06-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 71 events.
Biomarker capability evidence (55)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ALK | Trial sponsor | Named in trial inclusion criteria |
| CD34 | Trial collaborator | Named in trial inclusion criteria |
| MS4A1 | Trial collaborator | Named in trial inclusion criteria |
| MS4A1 | Trial sponsor | Named in trial inclusion criteria |
| NPPA | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 55 evidence rows.
Biomarkers this organization publishes on (156)
Shown in this order: most publications first.
Showing 5 of 156 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.